NCT03683433 2026-03-05
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
3 trialsNCT03383575 2026-02-17
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03515512 2025-10-14
IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Massachusetts General Hospital
Phase 1 Completed